Date published: 2026-6-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

Bortezomib (CAS 179324-69-7)

5.0(2)
Write a reviewAsk a question

See product citations (115)

Alternate Names:
Bortezomib also known as Velcade; Radiciol; LDP-341
Application:
Bortezomib is a selective and robust 26S proteasome inhibitor and is a boronic acid dipeptide derivative
CAS Number:
179324-69-7
Purity:
≥98%
Molecular Weight:
384.24
Molecular Formula:
C19H25BN4O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Bortezomib is a selective and robust 26S proteasome inhibitor, that is a boronic acid dipeptide derivative. Human pancreatic cancer cell studies demonstrate Bortezomib to inhibit the PKR-like endoplasmic reticulum (ER) kinase and enhance ER stress, leading to apoptosis. Studies suggest that Bortezomib affects the gene expression of WT1, and blocks the function of human plasmacytoid DCs through the inhibition of intracellular trafficking of Toll-like receptors and modification of the ER homeostasis. Additionally, Bortezomib has been reported to inhibit necrosis and cell proliferation, and downregulate metastatic gene expression. Bortezomib is an inhibitor of 20S Proteasome.


Bortezomib (CAS 179324-69-7) References

  1. Proteasome inhibition measurements: clinical application.  |  Lightcap, ES., et al. 2000. Clin Chem. 46: 673-83. PMID: 10794750
  2. Development of the proteasome inhibitor PS-341.  |  Adams, J. 2002. Oncologist. 7: 9-16. PMID: 11854543
  3. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.  |  Ling, YH., et al. 2003. Clin Cancer Res. 9: 1145-54. PMID: 12631620
  4. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.  |  Nawrocki, ST., et al. 2005. Cancer Res. 65: 11510-9. PMID: 16357160
  5. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.  |  Jones, MD., et al. 2010. Clin Cancer Res. 16: 4978-89. PMID: 20843837
  6. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.  |  Hirai, M., et al. 2011. Blood. 117: 500-9. PMID: 20956804
  7. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.  |  Alimena, G., et al. 2011. Leuk Res. 35: 504-7. PMID: 20971509
  8. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.  |  Dou, QP. and Zonder, JA. 2014. Curr Cancer Drug Targets. 14: 517-36. PMID: 25092212
  9. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.  |  Xia, J., et al. 2020. Mol Oncol. 14: 763-778. PMID: 31955515
  10. Bortezomib alleviates myocardial ischemia reperfusion injury via enhancing of Nrf2/HO-1 signaling pathway.  |  Liu, C., et al. 2021. Biochem Biophys Res Commun. 556: 207-214. PMID: 33848935
  11. Bortezomib-Induced Ovarian Toxicity in Mice.  |  Mutluay, D., et al. 2022. Toxicol Pathol. 50: 381-389. PMID: 35352576
  12. Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy.  |  Yue, Y., et al. 2022. Leuk Res. 122: 106949. PMID: 36113267
  13. Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion.  |  Snavely, AR., et al. 2022. Dis Model Mech. 15: PMID: 36398590

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Bortezomib, 2.5 mg

sc-217785
2.5 mg
$135.00

Bortezomib, 25 mg

sc-217785A
25 mg
$1085.00